[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HRP20200492T1 - Bromodomenski inhibitori - Google Patents

Bromodomenski inhibitori Download PDF

Info

Publication number
HRP20200492T1
HRP20200492T1 HRP20200492TT HRP20200492T HRP20200492T1 HR P20200492 T1 HRP20200492 T1 HR P20200492T1 HR P20200492T T HRP20200492T T HR P20200492TT HR P20200492 T HRP20200492 T HR P20200492T HR P20200492 T1 HRP20200492 T1 HR P20200492T1
Authority
HR
Croatia
Prior art keywords
methyl
oxopyridin
phenyl
difluorophenoxy
methylsulfonylphenyl
Prior art date
Application number
HRP20200492TT
Other languages
English (en)
Inventor
Michael John Bennett
Juan Manuel Betancort
Amogh Boloor
Stephen W. Kaldor
Jeffrey Alan Stafford
James Marvin Veal
Original Assignee
Celgene Quanticel Research, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Quanticel Research, Inc. filed Critical Celgene Quanticel Research, Inc.
Publication of HRP20200492T1 publication Critical patent/HRP20200492T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Claims (21)

1. Spoj Formule (II) ili njegova farmaceutski prihvatljiva sol, [image] naznačen time, da R2 je alkil, cikloalkil, cikloalkilalkil, heterociklilalkil, aralkil ili heteroarilalkil; X6 je C-H ili N; X5 je C-R5 ili N; pod uvjetom da ako X6 je N, tada X5 je C-R5 i ako X5 je N, tada X6 je CH; R5 je vodik, halogen, -OH, -CN, -OR61, -NHR61, -N(R61)2, alkil, cikloalkil, cikloalkilalkil, aril, aralkil, heterociklil, heterociklilalkil, heteroaril ili heteroarilalkil, gdje je svaki R61 neovisno odabran od alkila, cikloalkila, cikloalkilalkila, arila, aralkila, heterociklila, heterociklilalkila, heteroarila ili heteroarilalkila; R6 je vodik, halogen, -OH, -CN, alkil, cikloalkil, cikloalkilalkil, amino, alkilamino, dialkilamino, cikloalkilalkilamino, alkoksi, -S-alkil, cikloalkilalkoksi, heterociklil, araloksi, heteroariloksi, ariloksi, alkiniloksi ili -N(H)CO alkil; RA je [image] X2 je N ili C-R12, gdje je R12 vodik, halogen, alkil ili alkoksi; R13 je -Y-Z; Y je odabran od veze, -CH2- ili -CH(C1-C4 alkil)-; Z je odabran od -SO2R21, -N(R22)SO2R21, -SO2N(R22)2, -N(R22)SO2N(R22)2,-CON(R22)2, -N(R22)CO2R21, -N(R22)CON(R22)2, -N(R22)COR21, -COR21, -OC(O)N(R22)2, -OSO2N(R22)2 ili -N(R22)SO3R21; X3 je N ili C-R14, pri čemu je R14 vodik, halogen, -CN, alkil, cikloalkil ili alkoksi; X4 je N ili C-R15, pri čemu je R15 vodik, halogen, -CN, alkil, alkoksi, ariloksi, aralkiloksi, cikloalkilalkiloksi, heterocikliloksi, heteroarilalkiloksi ili alkiniloksi; R16 je vodik, halogen, -N(H)COX ili -W-X, u kojem W je veza, -O-, -S- ili - NH-, a X je odabran od alkila, arila, aralkila, cikloalkila, cikloalkilalkila, alkinila, cikloalkilalkinila, heterociklila, heterociklilalkila, heteroarila ili heteroarilalkila; svaki R21 je neovisno odabran od alkila, cikloalkila, cikloalkilalkila, arila, aralkila, heterociklila, heterociklilalkila, heteroarila ili heteroarilalkila; i svaki R22 je neovisno odabran od vodika, alkila, cikloalkila, cikloalkilalkila, arila, aralkila, heterociklila, heterociklilalkila, heteroarila ili heteroarilalkila.; te pod uvjetom da kada X6 je N, tada R5 i R6 nisu vodik.
2. Spoj u skladu s patentnim zahtjevom 1 ili njegova farmaceutski prihvatljiva sol kako je predstavljeno Formulom (IIa) [image] naznačen time, da R2 je CH3, CH2CH3, CH2CF3, CH2F, CHF2, CF3, CH2D, CHD2 ili CD3; X6 je C-H ili N; 55 X5 je C-R5 ili N; pod uvjetom da ako X6 je N, tada X5 je C-R5 i ako X5 je N, tada X6 je CH; R5 je vodik, halogen, -OH,-CN, -OR61, -NHR61, -N(R61)2, alkil, cikloalkil, cikloalkilalkil, aril, aralkil, heterociklil, heterociklilalkil, heteroaril ili heteroarilalkil, gdje je svaki R61 neovisno odabran od alkila, cikloalkila, cikloalkilalkila, arila, aralkila, heterociklila, heterociklilalkila, heteroarila ili heteroarilalkila; R6 je vodik, halogen, -OH, -CN, alkil, cikloalkil, cikloalkilalkil, amino, alkilamino, dialkilamino, cikloalkilalkilamino, alkoksi ili cikloalkilalkoksi; RA je [image] X2 je N ili C-R12, gdje R12 je vodik, halogen, alkil ili alkoksi; R13 je -Y-Z; Y je odabran od veze ili -CH2-; Z je odabran od -SO2R21, -N(R22)SO2R21, -SO2N(R22)2, -N(R22)SO2N(R22)2, - CON(R22)2, -N(R22)CO2R21, -N(R22)CON(R22)2, -N(R22)COR21, -OC(O)N(R22)2, - OSO2N(R22)2 ili -N(R22)SO3R21; X3 je N ili C-R14, gdje je R14 vodik, halogen, -CN, alkil, cikloalkil ili akoksi; X4 je N ili C-R15, gdje je R15 vodik, halogen, -CN, alkil ili akoksi; R16 je vodik, halogen ili -W-X, gdje W je veza, -O-, -S- ili -NH-, a X je odabran od alkila, arila, aralkila, cikloalkila, cikloalkilalkila, heterociklila, heterociklilalkila, heteroarila ili heteroarilalkila; svaki R21 je neovisno odabran od alkila, cikloalkila, cikloalkilalkila, arila, aralkila, heterociklila, heterociklilalkila, heteroarila ili heteroarilalkila; i svaki R22 je neovisno odabran od vodika, alkila, cikloalkila, cikloalkilalkila, arila, aralkila, heterociklila, heterociklilalkila, heteroarila ili heteroarilalkila; i pod uvjetom da kada X6 je N, tada R5 i R6 nisu vodik.
3. Spoj u skladu s patentnim zahtjevom 1 ili 2, naznačen time, da R2 je CH3 i/ili pri čemu X6 je C-H ili u kojem X6 je N.
4. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačen time, da X5 je C-R5.
5. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačen time, da X5 je N.
6. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-4, naznačen time, da je R5 vodik, halogen ili alkil ili u kojem je R6 vodik, halogen, alkil ili akoksi ili u kojem je R5 vodik, halogen ili alkil i R6 je vodik, halogen, alkil, ili alkoksi.
7. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-6, naznačen time, da je Y veza ili u kojem je Y - CH2-.
8. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-7, naznačen time, da je Z odabran iz skupine koja se sastoji od -SO2R21, -N(R22)SO2R21, -SO2N(R22)2, -N(R22)SO2N(R22)2, -CON(R22)2, -N(R22CO2R21 i -N(R22)CON(R22)2.
9. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-8, naznačen time, da R21 je alkil, cikloalkil ili cikloalkilalkil.
10. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-9, naznačen time, da R14 je vodik, halogen ili alkil.
11. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-10, naznačen time, da X4 je C-R15.
12. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-9 ili 11, naznačen time, da X3 je N.
13. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-12, naznačen time, da X2 je N.
14. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-9, naznačen time, da X2 i X3 si N, a X4 je C-H ili u kojem R21 je alkil X2 i X3 su N, a X4 je C-H.
15. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-14, naznačen time, da W je -O- ili pri čemu W je - NH- ili u kojem W je veza ili u kojem W je -O- i X je alkil ili u kojem W je -O- i X je aril ili u kojem W je -O- i X je cikloalkilalkil ili u kojem W je veza i X je alkil ili u kojem W je veza i X je aril ili u kojem W je veza i X je cikloalkilalkil.
16. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-15, naznačen time, da je X odabran iz skupine koja se sastoji od alkila, arila i cikloalkilalkila.
17. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-16, naznačen time, da R6 je CD3.
18. Spoj sukladno patentnom zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačen time, da je odabran od: N-[3-(1-metil-6-oksopiridin-3-il)fenil]metansulfonamida; N-[3-(1,4-dimetil-6-oksopiridin-3-il)fenil]metansulfonamida; N-[3-(1,5-dimetil-6-oksopiridin-3-il)fenil]metansulfonamida; N-[3-(1,4,5-trimetil-6-oksopiridin-3-il)fenil]metansulfonamida; 5-[2-(ciklopropilmetoksi)-5-metilsulfonilfenil]-1-metilpiridin-2-ona; N-[4-(2,4-difluorofenoksi)-3-(1-metil-6-oksopiridin-3-il)fenil]etansulfonamida; N-[4-(2,4-difluorofenoksi)-3-(1-metil-6-oksopiridin-3-il)fenil]metansulfonamida; N-[4-(2,4-difluorofenoksi)-3-(1,4-dimetil-6-oksopiridin-3-il)fenil]metansulfonamida; N-[4-(2,4-difluorofenoksi)-3-(1,5-dimetil-6-oksopiridin-3-il)fenil]metansulfonamida; N-[4-(2,4-difluorofenoksi)-3-(1,4,5-trimetil-6-oksopiridin-3-il)fenil]metansulfonamida; 3-amino-1-metil-5-(3-metilsulfonilfenil)pirazin-2-ona; 3-amino-5-(3-etilsulfonilfenil)-1-metilpirazin-2-ona; N-[5-(6-amino-4-metil-5-oksopirazin-2-il)-2-metoksifenil]metansulfonamida; 3-amino-1-metil-5-(3-metilsulfonilfenil)piridin-2-ona; 3-amino-5-(3-etilsulfonilfenil)-1-metilpiridin-2-ona; N-[5-(5-amino-1-metil-6-oksopiridin-3-il)-2-metoksifenil]metansulfonamida; N-[2-metoksi-5-[1-metil-5-(metilamino)-6-oksopiridin-3-il]fenil]metansulfonamida; N-[5-[5-(etilamino)-1-metil-6-oksopiridin-3-il]-2-metoksifenil]metansulfonamida; N-[5-[5-(ciklopropilmetilamino)-1-metil-6-oksopiridin-3-il]-2-metoksifenil]metansulfonamida; N-[5-[5-(dimetilamino)-1-metil-6-oksopiridin-3-il]-2-metoksifenil]metansulfonamida; N-[5-[5-(dietilamino)-1-metil-6-oksopiridin-3-il]-2-metoksifenil]metansulfonamida; N-[3-(5-amino-1-metil-6-oksopiridin-3-il)-4-(2,4-difluorofenoksi)fenil]etansulfonamida; 3-amino-5-[2-(ciklopropilmetoksi)-5-metilsulfonilfenil]-1-metilpiridin-2-ona; 4-etoksi-3-(1-metil-6-oksopiridin-3-il)benzensulfonamida; 4-(2,4-difluorofenoksi)-3-(1-metil-6-oksopiridin-3-il)benzensulfonamida; 5 - [2-(ciklopropilmetoksi)-5-metilsulfonilfenil]-3-fluoro-1-metilpiridin-2-ona; 5 - [2-(2,4-difluorofenoksi)-5 -metilsulfonilfenil]-3-fluoro-1-metilpiridin-2-ona; 5-[2-(2,4-difluorofenoksi)-5-etilsulfonilfenil]-3-fluoro-1-metilpiridin-2-ona; N-[4-(2,4-difluorofenoksi)-3-(5-fluoro-1-metil-6-oksopiridin-3-il)fenil]etansulfonamida; N-[3-(5-kloro-1-metil-6-oksopiridin-3-il)-4-(2,4-difluorofenoksi)fenil]etansulfonamida; 6-[2-(ciklopropilmetoksi)-5-metilsulfonilfenil]-2,4-dimetilpiridazin-3-ona; 6-[2-(ciklopropilmetoksi)-5-metilsulfonilfenil]-2,5-dimetilpiridazin-3-ona; N-[4-(2,4-difluorofenoksi)-3-[1-metil-6-okso-5-(trifluorometil)piridin-3-il]fenil]etansulfonamida; N-[4-(2,4-difluorofenoksi)-3-(4-fluoro-1-metil-6-oksopiridin-3-il)fenil]etansulfonamida; N-[3-(5-ciklopropil-1-metil-6-oksopiridin-3-il)-4-(2,4-difluorofenoksi)fenil]etansulfonamida; N-{4-(2,4-difluorofenoksi)-3-[1-(2H3)metil-6-oksopiridin-3-il]fenil}etansulfonamida; 5-[5-(ciklopropilmetoksi)-2-(metilsulfonilmetil)pirimidin-4-il]-1,3-dimetilpiridin-2-ona; 5-[5-(2,4-difluorofenoksi)-2-(metilsulfonilmetil)pirimidin-4-il]-3-metoksi-1-metilpiridin-2-ona; 5-[5-(2,4-difluorofenoksi)-2-(metilsulfonilmetil)pirimidin-4-il]-1,3-dimetilpiridin-2-ona; 5-[5-(2,4-difluorofenoksi)-2-metilsulfonilpirimidin-4-il]-1,3-dimetilpiridin-2-ona; 5-[5-(2,4-difluorofenoksi)-2-metilsulfonilpirimidin-4-il]-3-metoksi-1-metilpiridin-2-ona; N-[5-(ciklopropilmetoksi)-4-(1,5-dimetil-6-oksopiridin-3-il)pirimidin-2-il]metansulfonamida; N-[5-(ciklopropilmetoksi)-4-(1,5-dimetil-6-oksopiridin-3-il)pirimidin-2-il]-N-etilmetansulfonamida; N-[5-(2,4-difluorofenoksi)-4-(1,5-dimetil-6-oksopiridin-3-il)pirimidin-2-il]metansulfonamida; N-[5-(2,4-difluorofenoksi)-4-(5-metoksi-1-metil-6-oksopiridin-3-il)pirimidin-2-il]metansulfonamida; N-[5-(2,4-difluorofenoksi)-4-(5-metoksi-1-metil-6-oksopiridin-3-il)pirimidin-2-il]etansulfonamida; N-[5-(2,4-difluorofenoksi)-4-(1,5-dimetil-6-oksopiridin-3-il)pirimidin-2-il]etansulfonamida; [4-(ciklopropilmetoksi)-3-(1,5-dimetil-6-oksopiridin-3-il)fenil]sulfamata; N-[4-(2,4-difluorofenoksi)-3-(1,5-dimetil-6-oksopiridin-3-il)fenil]-N-metilmetansulfonamida; N-[4-(2,4-difluorofenoksi)-3-(1,5-dimetil-6-oksopiridin-3-il)fenil]-N-(oksetan-3-il)metansulfonamida; 5-[2-(ciklopropilmetoksi)-5-metilsulfonilfenil]-1-(ciklopropilmetil)-3-metilpiridin-2-ona; 5-[2-(ciklopropilmetoksi)-5-metilsulfonilfenil]-3-metil-1-(2-metilpropil)piridin-2-ona; 5-[2-(ciklopropilmetoksi)-5-metilsulfonilfenil]-1-(2-metoksietil)-3-metilpiridin-2-ona; 5-[2-(ciklopropilmetoksi)-5-metilsulfonilfenil]-3-metil-1-(oksetan-3-ilmetil)piridin-2-ona; 5-[2-(ciklopropilmetoksi)-5-metilsulfonilfenil]-3-metil-1-(1,3-oksazol-4-ilmetil)piridin-2-ona; N-[3-[1-(ciklopropilmetil)-5-metil-6-oksopiridin-3-il]-4-(2,4-difluorofenoksi)fenil]etansulfonamida; N-[4-[1-(ciklopropilmetil)-5-metil-6-oksopiridin-3-il]-5-(2,4-difluorofenoksi)pirimidin-2- il]metansulfonamida; N-[4-[1-(ciklopropilmetil)-5-metil-6-oksopiridin-3-il]-5-(2,4-difluorofenoksi)pirimidin-2-il]etansulfonamida; 1-(ciklopropilmetil)-5-[4-(2,4-difluorofenoksi)-1-(metilsulfonilmetil)-6-oksopiridin-3-il]-3-metilpiridin-2- ona; 1-ciklopropil-5-[2-(ciklopropilmetoksi)-5-etilsulfonilfenil]-3-metilpiridin-2-ona; N-[4-(2,4-difluorofenoksi)-3-(5-fluoro-1-metil-6-oksopiridin-3-il)fenil]metansulfonamida; 3-kloro-5-[2-(ciklopropilmetoksi)-5-etilsulfonilfenil]-1-metilpiridin-2-ona; 5 - [2-(ciklopropilmetoksi)-5-etilsulfonilfenil]-3-fluoro-1 -metilpiridin-2-ona; 3-kloro-5-[2-(ciklopropilmetilamino)-5-etilsulfonilfenil]-1-metilpiridin-2-ona; 5-[2-(2,4-difluorofenoksi)-5-(methanesulfonilmetil)fenil]-3-(2H3)metil-1-metil-1,2-dihidropiridin-2-ona; N-[4-(2,4-difluorofenoksi)-3-[5-(2H3)metil-1-metil-6-okso-1,6-dihidropiridin-3-il]fenil]metansulfonamida; N-[4-(2,4-difluorofenoksi)-3-[5-(2H3)metil-1-metil-6-okso-1,6-dihidropiridin-3-il]fenil]etan-1-sulfonamida; N-[3-(5-ciklopropil-1-metil-6-oksopiridin-3-il)-4-(2,4-difluorofenoksi)fenil]metansulfonamida; 3-ciklopropil-5-[2-(ciklopropilmetoksi)-5-etilsulfonilfenil]-1-metilpiridin-2-ona; N-[4-(2,4-difluorofenoksi)-3-(1-metil-6-okso-5-pirolidin-1-ilpiridin-3-il)fenil]metansulfonamida; 5-[2-(ciklopropilmetoksi)-5-etilsulfonilfenil]-1-metil-3-pirolidin-1-ilpiridin-2-ona; N-[4-(2,4-difluorofenoksi)-3-(5-etinil-1-metil-6-oksopiridin-3-il)fenil]etansulfonamida; 5-[2-(ciklopropilmetoksi)-5-etilsulfonilfenil]-3-etinil-1-metilpiridin-2-ona; 5-[2-(ciklopropilmetoksi)-5-metilsulfonilfenil]-3-etinil-1-metilpiridin-2-ona; N-[4-(2,4-difluorofenoksi)-3-(5-etinil-1-metil-6-oksopiridin-3-il)fenil]metansulfonamida; 5-[2-(ciklopropilmetoksi)-5-etilsulfonilfenil]-3-(difluorometoksi)-1-metilpiridin-2-ona; 5-[2-(ciklopropilmetoksi)-5-etilsulfonilfenil]-1-metil-3-(2,2,2-trifluoroetoksi)piridin-2-ona; N-[3-[5-(difluorometoksi)-1-metil-6-oksopiridin-3-il]-4-(2,4-difluorofenoksi)fenil]etansulfonamida; N-[4-(2,4-difluorofenoksi)-3-[1-metil-6-okso-5-(2,2,2-trifluoroetoksi)piridin-3-il]fenil]etansulfonamida; 3-(difluorometoksi)-5-[2-(2,4-difluorofenoksi)-5-(etilsulfonilmetil)fenil]-1-metilpiridin-2-ona; 5-[2-(2,4-difluorofenoksi)-5-(etilsulfonilmetil)fenil]-1-metil-3-(2,2,2-trifluoroetoksi)piridin-2-ona; 5-[2-(ciklopropilmetoksi)-5-metilsulfonilfenil]-1-metil-3-(1-metilpirazol-4-il)oksipiridin-2-ona; 5-[2-(ciklopropilmetoksi)-5-metilsulfonilfenil]-1-metil-3-(1-propan-2-ilpirazol-4-il)oksipiridin-2-ona; 5-[2-(ciklopropilmetoksi)-5-metilsulfonilfenil]-1-metil-3-fenoksipiridin-2-ona; N-[4-(1-butil-5-metil-6-oksopiridin-3-il)-5-(2,4-difluorofenoksi)pirimidin-2-il]metansulfonamida; N-[4-(1-butil-5-metil-6-oksopiridin-3-il)-5-(2,4-difluorofenoksi)pirimidin-2-il]etansulfonamida; N-[4-[1-(ciklobutilmetil)-5-metil-6-oksopiridin-3-il]-5-(2,4-difluorofenoksi)pirimidin-2- il]metansulfonamida; N-[4-[1-(ciklobutilmetil)-5-metil-6-oksopiridin-3-il]-5-(2,4-difluorofenoksi)pirimidin-2-il]etansulfonamida; 5-(5-etil-2-metilsulfonilpirimidin-4-il)-1,3-dimetilpiridin-2-ona; 1,3-dimetil-5-(2-metilsulfonil-5-propilpirimidin-4-il)piridin-2-ona; 5-(5-butil-2-metilsulfonilpirimidin-4-il)-1,3-dimetilpiridin-2-ona; N-[4-(1,5-dimetil-6-oksopiridin-3-il)-5-etilpirimidin-2-il]etansulfonamida; N-[4-(1,5-dimetil-6-oksopiridin-3-il)-5-propilpirimidin-2-il]etansulfonamida; N-[5-butil-4-(1,5-dimetil-6-oksopiridin-3-il)pirimidin-2-il]etansulfonamida; 5-(2-etil-5-metilsulfonilfenil)-1-metilpiridin-2-ona; 1-metil-5-(5-metilsulfonil-2-propilfenil)piridin-2-ona; 5-[2-(2-ciklopropiletil)-5-metilsulfonilfenil]-1-metilpiridin-2-ona; 5-(2-butil-5-metilsulfonilfenil)-1-metilpiridin-2-ona; 5-[3-[(4-metoksifenil)metoksi]-5-metilsulfonilfenil]-1,3-dimetilpiridin-2-ona; 1,3-dimetil-5-(3-metilsulfonil-5-fenilmetoksifenil)piridin-2-ona; 5-[3-(ciklopropilmetoksi)-5-metilsulfonilfenil]-1,3-dimetilpiridin-2-ona; 1,3-dimetil-5-[3-metilsulfonil-5-(2-feniletoksi)fenil]piridin-2-ona; 5-[3-(2-ciklopropiletoksi)-5-metilsulfonilfenil]-1,3-dimetilpiridin-2-ona; 1,3-dimetil-5-[3-metilsulfonil-5-(2,2,2-trifluoroetoksi)fenil]piridin-2-ona; 1,3-dimetil-5-[3-[(3-metiloksetan-3-il)metoksi]-5-metilsulfonilfenil]piridin-2-ona; 1,3-dimetil-5-[3-metilsulfonil-5-(piridin-2-ilmetoksi)fenil]piridin-2-ona; 5-[3-[(2,6-dimetilfenil)metoksi]-5-metilsulfonilfenil]-1,3-dimetilpiridin-2-ona; 5-[3-[(2-klorofenil)metoksi]-5-metilsulfonilfenil]-1,3-dimetilpiridin-2-ona; 5-[3-[[2-(difluorometoksi)fenil]metoksi]-5-metilsulfonilfenil]-1,3-dimetilpiridin-2-ona; 2-[[3-(1,5-dimetil-6-oksopiridin-3-il)-5-metilsulfonilfenoksi]metil]benzonitrila; 5-[3-[(2,4-difluorofenil)metoksi]-5-metilsulfonilfenil]-1,3-dimetilpiridin-2-ona; 1,3-dimetil-5-[3-metilsulfonil-5-(1-feniletoksi)fenil]piridin-2-ona; 5-[3-[(2,3-diklorofenil)metoksi]-5-metilsulfonilfenil]-1,3-dimetilpiridin-2-ona; 1,3-dimetil-5-[3-metilsulfonil-5-(piridin-3-ilmetoksi)fenil]piridin-2-ona; 3-[[3-(1,5-dimetil-6-oksopiridin-3-il)-5-metilsulfonilfenoksi]metil]benzonitrila; 5-(3-but-2-inoksi-5-metilsulfonilfenil)-1,3-dimetilpiridin-2-ona; 1,3-dimetil-5-[3-metilsulfonil-5-(1-feniletoksi)fenil]piridin-2-ona; N-[3-(2,4-difluorofenoksi)-5-(1,5-dimetil-6-oksopiridin-3-il)fenil]etansulfonamida; 4-[3 - [(4-metoksifenil)metoksi]-5-metilsulfonilfenil] -2-metilizokinolin-1-ona; 2-metil-4-(3-metilsulfonil-5-fenilmetoksifenil)izokinolin-1-ona; 4-[3-(ciklopropilmetoksi)-5-metilsulfonilfenil]-2-metilizokinolin-1-ona; N-[4-(2,4-difluorofenoksi)-6-(1,5-dimetil-6-oksopiridin-3-il)pirimidin-2-il]etansulfonamida; N-[2-(2,4-difluorofenoksi)-6-(1,5-dimetil-6-oksopiridin-3-il)pirimidin-4-il]etansulfonamida; 1-metil-5-(2-metilsulfonil-5-propilpirimidin-4-il)piridin-2-ona; 5-(5-butil-2-metilsulfonilpirimidin-4-il)-il)-1-metilpiridin-2-ona; 3-kloro-1-metil-5-(2-metilsulfonil-5-propilpirimidin-4-il)piridin-2-ona; 5-(5-butil-2-metilsulfonilpirimidin-4-il)-3-kloro-1-metilpiridin-2-ona; 3-metoksi-1-metil-5-(2-metilsulfonil-5-propilpirimidin-4-il)piridin-2-ona; 5-(5-butil-2-metilsulfonilpirimidin-4-il)-3-metoksi-1 -metilpiridin-2-ona; N-[4-(1-metil-6-oksopiridin-3-il)-5-propilpirimidin-2-il]etansulfonamida; N-[5-butil-4-(1-metil-6-oksopiridin-3-il)pirimidin-2-il]etansulfonamida; N-[4-(5-kloro-1-metil-6-oksopiridin-3-il)-5-propilpirimidin-2-il]etansulfonamida; N-[5-butil-4-(5-kloro-1-metil-6-oksopiridin-3-il)pirimidin-2-il]etansulfonamida; N-[4-(5-metoksi-1-metil-6-oksopiridin-3-il)-5-propilpirimidin-2-il]etansulfonamida; N-[5-butil-4-(5-metoksi-1-metil-6-oksopiridin-3-il)pirimidin-2-il]etansulfonamida; N-[5-butil-4-(1,5-dimetil-6-oksopiridin-3-il)pirimidin-2-il]metansulfonamida; 5-(2-but-2-inoksi-5-metilsulfonilfenil)-1,3-dimetilpiridin-2-ona; 5-(2-but-2-inoksi-5-etilsulfonilfenil)-3-metoksi-1-metilpiridin-2-ona; 5-(5-etilsulfonil-2-pent-2-inoksifenil)-3-metoksi-1 -metilpiridin-2-ona; 5-[2-(3-ciklopropilprop-2-inoksi)-5-etilsulfonilfenil]-3-metoksi-1-metilpiridin-2-ona; 5-[2-(2,4-difluorofenoksi)-5-etilsulfonilfenil]-1-metil-3-(trifluorometil)piridin-2-ona; 5-[2-(ciklopropilmetoksi)-5-propan-2-ilsulfonilfenil]-1,3-dimetilpiridin-2-ona; N-[3-(1,5-dimetil-6-oksopiridin-3-il)-5-fenilmetoksifenil]etansulfonamida; 5-[2-(2,4-difluoroanilino)-5-etilsulfonilfenil]-1,3-dimetilpiridin-2-ona; 5-[2-[(4,4-difluorocikloheksil)amino]-5-etilsulfonilfenil]-1,3-dimetilpiridin-2-ona; 5-[2-(2,4-difluoroanilino)-5-metilsulfonilfenil]-1,3-dimetilpiridin-2-ona; 5-[2-(ciklopropilmetoksi)-5-etilsulfonilfenil]-3-metoksi-1-metilpiridin-2-ona; 5-[2-(2,4-difluorofenoksi)-5-(metilsulfonilmetil)fenil]-3-metoksi-1-metilpiridin-2-ona; 5-[2-(4-hidroksicikloheksil)oksi-5-metilsulfonilfenil]-1,3-dimetilpiridin-2-ona; N-[4-(2,4-difluorofenoksi)-3-(1-metil-5-metilsulfanil-6-oksopiridin-3-il)fenil]etansulfonamida; 5-[2-(4-aminocikloheksil)oksi-5-metilsulfonilfenil]-1,3-dimetilpiridin-2-ona; 5-[2-(4-aminocikloheksil)oksi-5-metilsulfonilfenil]-1,3-dimetilpiridin-2-ona; 1,3-dimetil-5-[5-metilsulfonil-2-(3,3,3-trifluoropropoksi)fenil]piridin-2-ona; 5-[2-(2,4-difluorofenoksi)-5-(metilsulfonilmetil)fenil]-1-(2-hidroksietil)-3-metilpiridin-2-ona; 5-[5-(etilsulfonilmetil)-2-(2,2,2-trifluoroetoksi)fenil]-1-(2-hidroksietil)-3 -metilpiridin-2-ona; 5-[2-(ciklopropilmetilamino)-5-etilsulfonilfenil]-1-metil-3-(metilamino)piridin-2-ona; 5-[2-(ciklopropilmetoksi)-5-etilsulfonilfenil]-1-metil-3-(metilamino)piridin-2-ona; N-[4-(2,4-difluorofenoksi)-3-[1-metil-5-(metilamino)-6-oksopiridin-3-il]fenil]etansulfonamida; 5-[5-(etilsulfonilmetil)-2-(2,2,2-trifluoroetoksi)fenil]-1,3-dimetilpiridin-2-ona; N-[4-(2,4-difluorofenoksi)-3-[1-metil-5-(metilamino)-6-oksopiridin-3-il]fenil]metansulfonamida; 5-[2-[(4,4-difluorocikloheksil)amino]-5-metilsulfonilfenil]-1,3-dimetilpiridin-2-ona; 5-[2-(ciklopropilmetilamino)-5-etilsulfonilfenil]-3-metoksi-1-metilpiridin-2-ona; 5-[2-(4,4-difluorocikloheksil)oksi-5-metilsulfonilfenil]-1,3-dimetilpiridin-2-ona; 5-[2-(ciklopentilamino)-5-etilsulfonilfenil]-1,3-dimetilpiridin-2-ona; 5-[2-(ciklopentilamino)-5-metilsulfonilfenil]-1,3-dimetilpiridin-2-ona; 3-kloro-1-metil-5-[5-(metilsulfonilmetil)-2-(2,2,2-trifluoroetoksi)fenil]piridin-2-ona; 5-(2-ciklopentiloksi-5-metilsulfonilfenil)-1,3-dimetilpiridin-2-ona; 1.3-dimetil-5-[5-metilsulfonil-2-(oksan-4-iloksi)fenil]piridin-2-ona; 3-fluoro-1-metil-5-[5-(metilsulfonilmetil)-2-(2,2,2-trifluoroetoksi)fenil]piridin-2-ona; 5-[2-(ciklopropilmetilamino)-5-metilsulfonilfenil]-1,4-dimetilpiridin-2-ona; 5-[2-(ciklopropilmetilamino)-5-etilsulfonilfenil]-1,4-dimetilpiridin-2-ona; 1.3-dimetil-5-[5-metilsulfonil-2-(oksolan-3-ilamino)fenil]piridin-2-ona; 1.3-dimetil-5-[5-metilsulfonil-2-(oksolan-3-iloksi)fenil]piridin-2-ona; 1.3-dimetil-5-[5-(metilsulfonilmetil)-2-(2,2,2-trifluoroetoksi)fenil]piridin-2-ona; 5-[2-(ciklopropilmetilamino)-5-metilsulfonilfenil]-1-etil-3-metilpiridin-2-ona; 5-[2-(2,4-difluorofenoksi)-5-(metilsulfonilmetil)fenil]-1-etil-3-metilpiridin-2-ona; N-[3-(1,5-dimetil-6-oksopiridin-3-il)-4-(4-hidroksicikloheksil)oksifenil]etansulfonamida; N-[3-(1,5-dimetil-6-oksopiridin-3-il)-4-(4-hidroksicikloheksil)oksifenil]etansulfonamida; N-[3-(1,5-dimetil-6-oksopiridin-3-il)-4-(4-hidroksicikloheksil)oksifenil]metansulfonamida; N-[3-(1,5-dimetil-6-oksopiridin-3-il)-4-(4-hidroksicikloheksil)oksifenil]metansulfonamida; 1.3-dimetil-5-[5-metilsulfonil-2-(oksan-4-ilamino)fenil]piridin-2-ona; 5-[2-(2,4-difluorofenoksi)-5-(metilsulfonilmetil)fenil]-3-fluoro-1-metilpiridin-2-ona; 5-[2-(ciklopropilmetilamino)-5-metilsulfonilfenil]-3-(dimetilamino)-1-metilpiridin-2-ona; N-[3-(1,5-dimetil-6-oksopiridin-3-il)-4-(oksan-4-iloksi)fenil]metansulfonamida; 5-[2-(ciklopropilmetilamino)-5-etilsulfonilfenil]-3-(dimetilamino)-1-metilpiridin-2-ona; N-[3-(1,5-dimetil-6-oksopiridin-3-il)-4-(oksan-4-iloksi)fenil]etansulfonamida; N-[4-(2,4-difluorofenoksi)-3-(5-metoksi-1-metil-6-oksopiridin-3-il)fenil]metansulfonamida; N-[4-(2,4-difluorofenoksi)-3-(5-metoksi-1-metil-6-oksopiridin-3-il)fenil]etansulfonamida; N-[3-(1,5-dimetil-6-oksopiridin-3-il)-4-(oksolan-3-iloksi)fenil]metansulfonamida; N-[3-(1,5-dimetil-6-oksopiridin-3-il)-4-(oksolan-3-iloksi)fenil]etansulfonamida; N-[3-(1,5-dimetil-6-oksopiridin-3-il)-4-(oksan-3-iloksi)fenil]metansulfonamida; N-[4-(4,4-difluorocikloheksil)oksi-3-(1,5-dimetil-6-oksopiridin-3-il)fenil]metansulfonamida; N-[3-(1,5-dimetil-6-oksopiridin-3-il)-4-(oksan-3-iloksi)fenil]etansulfonamida; N-[4-(4,4-difluorocikloheksil)oksi-3-(1,5-dimetil-6-oksopiridin-3-il)fenil]etansulfonamida; 5 - [2-(ciklopropilmetoksi)-5-etilsulfonilfenil] -1,3-dimetilpiridin-2-ona; N-[4-(2,4-difluorofenoksi)-3-(5-hidroksi-1-metil-6-oksopiridin-3-il)fenil]etansulfonamida; 4-(ciklopropilmetilamino)-3-(1,5-dimetil-6-oksopiridin-3-il)benzenesulfonamida; 4-(ciklopropilmetilamino)-3-(1-metil-6-oksopiridin-3-il)benzenesulfonamida; 5-[2-(2,4-difluorofenoksi)-5-(metilsulfonilmetil)fenil]-1,4-dimetilpiridin-2-ona; 5-[2-(2,4-difluorofenoksi)-5-(metilsulfonilmetil)fenil]-1,3-dimetilpiridin-2-ona; 5-(2-etoksi-5-etilsulfonilfenil)-1-(2H3)metil-4-metilpiridin-2-one; 5 - [2-(ciklopropilmetoksi)-5-etilsulfonilfenil]-1-(2H3)metil-4-metilpiridin-2-ona; 5-(2-etoksi-5-etilsulfonilfenil)-1,4-dimetilpiridin-2-ona; 5-[2-(ciklobutilmetoksi)-5-metilsulfonilfenil]-1,3-dimetilpiridin-2-ona; 5-[2-(ciklobutilmetoksi)-5-metilsulfonilfenil]-1-metilpiridin-2-ona; 5-(5-etilsulfonil-2-metoksifenil)-3-hidroksi-1-metilpiridin-2-ona; 5 - [2-(ciklopropilmetilamino)-5 -metilsulfonilfenil]-1,3-dimetilpiridin-2-ona; N-[4-(2,4-difluorofenoksi)-3-[5-(dimetilamino)-1-metil-6-oksopiridin-3-il]fenil]metansulfonamida; N-[4-(2,4-difluorofenoksi)-3-[5-(dimetilamino)-1-metil-6-oksopiridin-3-il]fenil]etansulfonamida; 5 - [2-(ciklopropilmetilamino)-5-etilsulfonilfenil]-1,3-dimetilpiridin-2-ona; 5 - [2-(ciklopropilmetoksi)-5-etilsulfonilfenil]-1,4-dimetilpiridin-2-ona; N-[3-(5-hidroksi-1-metil-6-oksopiridin-3-il)fenil]metansulfonamida; 5 - [2-(ciklopropilmetilamino)-5-metilsulfonilfenil]-1-metilpiridin-2-ona; 3 -(dimetilamino)-5 -(2-etoksi-5-etilsulfonilfenil)-1-metilpiridin-2-ona; 5 - [2-(2,4-difluorofenoksi)-5 -(metilsulfonilmetil)fenil]-1-metilpiridin-2-ona; N-[3-(1-metil-6-okso-5-fenilmetoksipiridin-3-il)fenil]metansulfonamida; N-[4-(2,4-difluorofenoksi)-3-(1,5-dimetil-6-oksopiridin-3-il)fenil]etansulfonamida; 5 - [2-(ciklopropilmetilamino)-5-etilsulfonilfenil]-1-metilpiridin-2-ona; 5-[2-(ciklopropilmetoksi)-5-metilsulfonilfenil]-3-(dimetilamino)-1-metilpiridin-2-ona; 5 - [4-fluoro-2-metoksi-5-(metilsulfonilmetil)fenil]-1-metilpiridin-2-ona; 5 - [2-(ciklopropilmetoksi)-5-metilsulfonilfenil]-1,3-dimetilpiridin-2-ona; 5-[2-(ciklopropilmetoksi)-5-metilsulfonilfenil]-1,4-dimetilpiridin-2-ona; N-[6-[3-(metansulfonamido)fenil]-4-metil-3-oksopirazin-2-il]acetamida; N-[3-(1,4-dimetil-6-oksopiridazin-3-il)fenil]etansulfonamida; N-[3-(1,5-dimetil-6-oksopiridazin-3-il)fenil]etansulfonamida; N-[5-[3-(metansulfonamido)fenil]-1-metil-2-oksopiridin-3-il]propanamida; N-[5-[3-(metansulfonamido)pheny1]-1-metil-2-oksopiridin-3-il]acetamida; 1-ciklobutil-5-[2-(ciklopropilmetoksi)-5-metilsulfonilfenil]-3-metilpiridin-2-ona; N-[3-(1-ciklobutil-5-metil-6-oksopiridin-3-il)-4-(2,4-difluorofenoksi)fenil]metansulfonamida; 1-benzil-5-[2-(ciklopropilmetoksi)-5-metilsulfonilfenil]-3-metilpiridin-2-ona; 5-(5-butil-2-metilsulfonilpirimidin-4-il)-3-metil-1-propan-2-ilpiridin-2-ona; N-[5-(2,4-difluorofenoksi)-4-(5-metil-6-okso-1-propan-2-ilpiridin-3-il)pirimidin-2-il]etansulfonamida; 5-[5-(2,4-difluorofenoksi)-2-metilsulfonilpirimidin-4-il]-3-metil-1-propan-2-ilpiridin-2-ona; N-[5-butil-4-(5-metil-6-okso-1-propan-2-ilpiridin-3-il)pirimidin-2-il]etansulfonamida; N-[5-butil-4-(1-metil-6-okso-5-propan-2-ilpiridin-3-il)pirimidin-2-il]etansulfonamida; 5-(5-butil-2-metilsulfonilpirimidin-4-il)-il)-1-metil-3-propan-2-ilpiridin-2-ona; N-[5-(2,4-difluorofenoksi)-4-(1-metil-6-okso-5-propan-2-ilpiridin-3-il)pirimidin-2-il]etansulfonamida; ili 5-[5-(2,4-difluorofenoksi)-2-metilsulfonilpirimidin-4-il]-1-metil-3-propan-2-ilpiridin-2-ona.
19. Farmaceutski pripravak, naznačen time, da sadrži spoj Formule (II) ili spoj prema patentnom zahtjevu 18 ili njegovu farmaceutski prihvatljivu sol i farmaceutski prihvatljivu pomoćnu tvar.
20. Spoj Formule (II) ili spoj iz patentnog zahtjeva 18 ili farmaceutski pripravak u skladu s patentnim zahtjevom 19, naznačen time, da se koristi kao lijek.
21. Spoj Formule (II) ili spoj iz patentnog zahtjeva 18 ili farmaceutski pripravak u skladu s patentnim zahtjevom 19, naznačen time, da se koristi kao lijek za liječenje karcinoma.
HRP20200492TT 2013-10-18 2020-03-25 Bromodomenski inhibitori HRP20200492T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361893133P 2013-10-18 2013-10-18
US201461931467P 2014-01-24 2014-01-24
EP17175464.1A EP3290407B1 (en) 2013-10-18 2014-10-17 Bromodomain inhibitors

Publications (1)

Publication Number Publication Date
HRP20200492T1 true HRP20200492T1 (hr) 2020-06-26

Family

ID=52826700

Family Applications (3)

Application Number Title Priority Date Filing Date
HRP20221389TT HRP20221389T1 (hr) 2013-10-18 2014-10-17 Inhibitori bromodomena
HRP20200341TT HRP20200341T1 (hr) 2013-10-18 2020-02-28 Bromodomenski (bet) inhibitori
HRP20200492TT HRP20200492T1 (hr) 2013-10-18 2020-03-25 Bromodomenski inhibitori

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HRP20221389TT HRP20221389T1 (hr) 2013-10-18 2014-10-17 Inhibitori bromodomena
HRP20200341TT HRP20200341T1 (hr) 2013-10-18 2020-02-28 Bromodomenski (bet) inhibitori

Country Status (31)

Country Link
US (8) US9034900B2 (hr)
EP (4) EP3057586B1 (hr)
JP (2) JP6445574B2 (hr)
KR (1) KR102311573B1 (hr)
CN (2) CN108558889B (hr)
AU (2) AU2014337064B2 (hr)
BR (1) BR112016008593B1 (hr)
CA (2) CA3148196A1 (hr)
CL (2) CL2016000925A1 (hr)
CR (1) CR20160229A (hr)
CY (2) CY1122734T1 (hr)
DK (3) DK3290407T3 (hr)
EA (1) EA035727B1 (hr)
ES (3) ES2774318T3 (hr)
FI (1) FI3640241T3 (hr)
HR (3) HRP20221389T1 (hr)
HU (2) HUE060767T2 (hr)
IL (2) IL245074B (hr)
LT (3) LT3057586T (hr)
MX (1) MX371386B (hr)
NI (1) NI201600056A (hr)
PE (2) PE20180248A1 (hr)
PH (1) PH12016500722A1 (hr)
PL (3) PL3640241T3 (hr)
PT (3) PT3290407T (hr)
RS (3) RS63733B1 (hr)
SA (1) SA516370965B1 (hr)
SG (2) SG11201602996RA (hr)
SI (3) SI3290407T1 (hr)
TW (2) TWI676619B (hr)
WO (1) WO2015058160A1 (hr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015022782A2 (pt) * 2013-03-14 2017-07-18 Glaxosmithkline Ip No 2 Ltd composto, composição farmacêutica, combinação, e, uso de um composto
EP3581576B1 (en) 2013-03-15 2022-01-26 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors for use in the treatment of a proliferative disease in combination with a janus kinase inhibitor
SI3290407T1 (sl) 2013-10-18 2020-07-31 Celgene Quanticel Research, Inc Inhibitorji bromodomene
CN105939996A (zh) * 2013-12-09 2016-09-14 艾伯维公司 用作布罗莫结构域抑制剂的二氢吡啶酮和二氢哒嗪酮衍生物
WO2015095492A1 (en) 2013-12-19 2015-06-25 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
CA2946731C (en) 2014-04-23 2022-06-07 Incyte Corporation 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins
SG11201609033TA (en) 2014-05-01 2016-11-29 Celgene Quanticel Res Inc Inhibitors of lysine specific demethylase-1
EP3194406B8 (en) 2014-09-15 2021-03-31 Incyte Corporation Tricyclic heterocycles for use as bet protein inhibitors
MA41614A (fr) 2015-02-25 2018-01-02 Alios Biopharma Inc Composés antiviraux
US11319318B2 (en) * 2015-03-05 2022-05-03 Boehringer Ingelheim International Gmbh Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9
AR104259A1 (es) 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
US10702517B2 (en) * 2015-04-22 2020-07-07 Celgene Quanticel Research, Inc. Bromodomain inhibitor
TW201642860A (zh) * 2015-04-22 2016-12-16 塞爾基因定量細胞研究公司 布羅莫結構域抑制劑
MX2018001756A (es) 2015-08-12 2018-09-06 Neomed Inst Benzimidazoles sustituidos, su preparacion y su uso como productos farmaceuticos.
WO2017075377A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
CN105254635A (zh) * 2015-10-30 2016-01-20 中国药科大学 一类咪唑并吡嗪类化合物及其药物组合物和用途
KR20180095935A (ko) * 2015-12-24 2018-08-28 셀젠 콴티셀 리서치, 인크. 브로모도메인 및 엑스트라-말단 단백질 억제제 병용 요법
US10550091B2 (en) 2016-03-25 2020-02-04 St. Jude Children's Research Hospital 1,4,5-substituted 1,2,3-triazole analogues as antagonists of the pregnane X receptor
MY190795A (en) * 2016-04-15 2022-05-12 Abbvie Inc Bromodomain inhibitors
WO2017184462A1 (en) 2016-04-18 2017-10-26 Celgene Quanticel Research, Inc. Therapeutic compounds
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
SG10201912398PA (en) 2016-06-20 2020-02-27 Incyte Corp Crystalline solid forms of a bet inhibitor
EP3474900A4 (en) 2016-06-23 2020-03-11 Dana-Farber Cancer Institute, Inc. DEGRADATION OF PROTEIN 9 (BRD9) CONTAINING BROMANOMAIN BY CONJUGATING BRD9 INHIBITORS WITH E3 LIGASE LIGAND AND METHOD FOR USE THEREOF
KR102470130B1 (ko) * 2016-07-18 2022-11-24 내셔널 인스티튜트 오브 바이올로지칼 사이언시스, 베이징 아폽토시스 억제제
WO2018075796A1 (en) * 2016-10-20 2018-04-26 Celgene Quanticel Research, Inc Bromodomain inhibitor
DK3532059T3 (da) * 2016-10-27 2022-03-14 Celgene Quanticel Res Inc Kombinationsterapi med bromdomæne- og ekstraterminal proteinhæmmer
CN108069958A (zh) * 2016-11-10 2018-05-25 凯惠科技发展(上海)有限公司 一种含氮杂环类化合物、其制备方法、药物组合物及应用
CN108069959A (zh) * 2016-11-10 2018-05-25 凯惠科技发展(上海)有限公司 一种含氮杂环类化合物、其制备方法、药物组合物及应用
JP7442439B2 (ja) 2017-03-30 2024-03-04 アルベルト－ルートヴィヒ－ユニバーシティー フライブルク Ｋｄｍ４阻害剤
TW202332436A (zh) * 2017-04-18 2023-08-16 美商塞爾基因定量細胞研究公司 治療用化合物
CA3073543A1 (en) * 2017-08-21 2019-02-28 Vivace Therapeutics, Inc. Benzosulfonyl compounds
CA3084648A1 (en) 2017-12-06 2019-06-13 Vivace Therapeutics, Inc. Benzocarbonyl compounds
WO2019141131A1 (zh) 2018-01-16 2019-07-25 中国科学院上海药物研究所 溴结构域抑制剂化合物及其用途
EP3746135A4 (en) 2018-01-30 2022-03-09 Foghorn Therapeutics Inc. METHODS AND COMPOUNDS FOR TREATMENT OF DISEASE
US20210261539A1 (en) * 2018-02-06 2021-08-26 Shanghai Haihe Pharmaceutical Co., Ltd. Compound having bet inhibitory activity and preparation method and use therefor
EP3793551A4 (en) 2018-05-16 2022-01-26 Vivace Therapeutics, Inc. OXADIAZOLE COMPOUNDS
JP7434274B2 (ja) 2018-07-23 2024-02-20 セルジーン・クオンティセル・リサーチ・インコーポレイテッド ブロモドメイン阻害剤の合成方法
EP3846800A4 (en) * 2018-09-04 2022-08-24 C4 Therapeutics, Inc. COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1
CN109180579A (zh) * 2018-10-29 2019-01-11 四川大学 一种4-碘异喹啉酮的高效合成法
US11192900B2 (en) 2018-10-30 2021-12-07 Nuvation Bio Inc. Substituted 1,6-dihydropyridinones and 1,2-dihydroisoquinolinones as bet inhibitors
TW202104207A (zh) * 2019-04-17 2021-02-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
CN112174945B (zh) * 2019-07-02 2022-06-07 四川大学 具有抗癌作用的吲唑类化合物及其制备方法和用途
KR102677015B1 (ko) * 2019-07-02 2024-06-19 누베이션 바이오 인크. Bet 억제제로서의 헤테로시클릭 화합물
CN112625036A (zh) * 2019-10-08 2021-04-09 上海海和药物研究开发股份有限公司 一类具有brd4抑制活性的化合物、其制备方法及用途
EP4096651A4 (en) 2020-01-29 2024-01-24 Foghorn Therapeutics Inc. COMPOUNDS AND THEIR USES
CN113264930B (zh) * 2020-02-17 2022-07-29 中国药科大学 吡咯类bet抑制剂及其制备方法与应用
CN113387879B (zh) * 2020-03-14 2023-05-30 成都先导药物开发股份有限公司 一种胺类衍生物、其制备方法及其在医药上的应用
EP4143166A4 (en) * 2020-04-29 2024-10-30 Nuvation Bio Inc HETEROCYCLIC COMPOUNDS AS BET INHIBITORS
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
US11787800B2 (en) 2020-07-29 2023-10-17 Foghorn Therapeutics Inc. BRD9 degraders and uses thereof
AU2021332217A1 (en) 2020-08-25 2023-05-11 Eli Lilly And Company Polymorphs of an ssao inhibitor
JP2024507232A (ja) 2021-02-22 2024-02-16 セルジーン・クオンティセル・リサーチ・インコーポレイテッド 前立腺がんの治療に用いるブロモドメイン（ｂｅｔ）阻害剤
WO2023283263A1 (en) 2021-07-06 2023-01-12 Foghorn Therapeutics Inc. Citrate salt, pharmaceutical compositions, and methods of making and using the same
EP4398989A1 (en) 2021-09-10 2024-07-17 Gilead Sciences, Inc. Thienopyrrole compounds
AU2022387426A1 (en) 2021-11-10 2024-05-16 Celgene Quanticel Research, Inc. Bet inhibitor for treating glioblastoma
CN116135858A (zh) * 2021-11-16 2023-05-19 中国科学院广州生物医药与健康研究院 一种呋喃并吡啶酮类化合物及其应用
CN114316261B (zh) * 2022-01-09 2023-05-26 广西大学 一种三嗪框架多相催化剂及其制备方法与应用
WO2023141522A2 (en) * 2022-01-21 2023-07-27 Slap Pharmaceuticals Llc Multicyclic compounds
WO2023173017A1 (en) * 2022-03-09 2023-09-14 Blossomhill Therapeutics, Inc. Kras inhibitors for treating disease
CN117229202B (zh) * 2023-11-15 2024-01-26 苏州美诺医药科技有限公司 一种brd9靶向降解化合物的中间体的制备方法

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2011970A1 (en) 1970-03-13 1971-11-18 CH. Boehringer Sohn, 6507 Ingelheim Imidazo-(1, 2-a)- pyrimidines prepn
US3635667A (en) 1970-07-23 1972-01-18 Fmc Corp Drycleaning with hydrogen peroxide
BE786028A (fr) 1971-07-08 1973-01-08 Boehringer Sohn Ingelheim 2,3-dihydro-oxo-imidazo(1,2-a)-pyrimidines, leurs sels d'addition avec des acides et procedes pour les fabriquer
DE2356005A1 (de) 1973-11-09 1975-05-22 Boehringer Sohn Ingelheim Neue 7-amino-imidazo eckige klammer auf 1,2-a eckige klammer zu pyrimidine, diese enthaltende arzneimittel sowie verfahren zu deren herstellung
AU577105B2 (en) 1985-04-02 1988-09-15 T.P.O. :Pharmachim: Acylaminic penicillin derivatives
US5466697A (en) * 1994-07-13 1995-11-14 Syntex (U.S.A.) Inc. 8-phenyl-1,6-naphthyridin-5-ones
US6117940A (en) 1997-10-17 2000-09-12 Mjalli; Adnan M. M. Amino-ketone solid support templates
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
JP2004143134A (ja) * 2002-02-13 2004-05-20 Takeda Chem Ind Ltd Ｊｎｋ阻害剤
AU2003211931A1 (en) 2002-02-13 2003-09-04 Takeda Chemical Industries, Ltd. Jnk inhibitor
ES2195785B1 (es) * 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
MXPA05002004A (es) 2002-09-26 2005-04-28 Pfizer Derivados de pirazol.
FR2847253B1 (fr) * 2002-11-19 2007-05-18 Aventis Pharma Sa Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
ES2211344B1 (es) * 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
JP2005089352A (ja) 2003-09-16 2005-04-07 Kissei Pharmaceut Co Ltd 新規なイミダゾ［１，５−ａ］ピラジン誘導体、それを含有する医薬組成物およびそれらの用途
US7723352B2 (en) * 2003-09-23 2010-05-25 Merck Sharp & Dohme Isoquinolinone potassium channel inhibitors
KR100703068B1 (ko) 2003-12-30 2007-04-05 에스케이케미칼주식회사 피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물
KR20070008674A (ko) 2004-04-01 2007-01-17 아스테라스 세이야쿠 가부시키가이샤 피라진 유도체, 및 아데노신 길항제로서의 이의 약학적용도
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
KR101357524B1 (ko) * 2005-03-10 2014-02-03 질레드 코네티컷 인코포레이티드 특정 치환된 아미드, 그의 제조 방법, 및 사용 방법
KR100781704B1 (ko) 2005-04-20 2007-12-03 에스케이케미칼주식회사 피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
UA93882C2 (ru) 2005-07-26 2011-03-25 Санофи-Авентис Пиперидинил-замещенные производные изохинолона kak ингибиторы rho-киназы
JP5049970B2 (ja) 2005-07-26 2012-10-17 サノフイ Ｒｈｏ−キナーゼ阻害剤としてのシクロヘキシルアミンイソキノロン誘導体
US20070099911A1 (en) 2005-10-28 2007-05-03 Wyeth Pyrroloquinolinone derivatives as 5-hydroxytryptamine-6 ligands
DE102005057924A1 (de) 2005-12-05 2007-06-06 Merck Patent Gmbh Pyridazinonderivate
PE20080839A1 (es) 2006-09-11 2008-08-23 Cgi Pharmaceuticals Inc Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
EA200900819A1 (ru) * 2006-12-22 2010-02-26 Новартис Аг Хиназолины для ингибирования pdk1
MX2009005825A (es) 2006-12-27 2009-06-16 Sanofi Aventis Derivados de isoquinolina e isoquinolinona sustituidos en calidad de inhibidores de rho-quinasa.
KR101474228B1 (ko) 2006-12-27 2014-12-18 사노피 사이클로알킬아민 치환된 이소퀴놀론 유도체
EP2102164B1 (en) 2006-12-27 2010-12-01 Sanofi-Aventis Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives
US8466150B2 (en) * 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
US8314087B2 (en) * 2007-02-16 2012-11-20 Amgen Inc. Nitrogen-containing heterocyclyl ketones and methods of use
AU2008251504B2 (en) * 2007-05-09 2013-07-18 Vertex Pharmaceuticals Incorporated Modulators of CFTR
DE102007025718A1 (de) 2007-06-01 2008-12-04 Merck Patent Gmbh Pyridazinonderivate
DE102007032507A1 (de) * 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
WO2009029214A1 (en) 2007-08-23 2009-03-05 Amgen Inc. Isoquinolone derivatives as phosphodiesterase 10 inhibitors
CL2008002793A1 (es) * 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
SG185330A1 (en) 2007-10-23 2012-11-29 Hoffmann La Roche Novel kinase inhibitors
WO2009097567A1 (en) 2008-01-30 2009-08-06 Cephalon, Inc. Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands
EP2313408B1 (en) 2008-06-25 2012-07-11 Bristol-Myers Squibb Company Diketopiperidine derivatives as hiv attachment inhibitors
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
JP5405592B2 (ja) * 2008-12-23 2014-02-05 エフ．ホフマン−ラ ロシュ アーゲー Ｐ２ｘ７モジュレーターとしてのジヒドロピリドンアミド
WO2011012592A1 (en) * 2009-07-30 2011-02-03 F. Hoffmann-La Roche Ag Dihydropyrimidone amides as p2x7 modulators
EP2280088A1 (de) 2009-07-31 2011-02-02 Siemens Aktiengesellschaft Vorrichtung zum Kippen eines metallurgischen Schmelzgefäßes, metallurgische Schmelzanordnung und Verfahren unter Verwendung einer solchen Schmelzanordnung
IL302896A (en) 2009-10-06 2023-07-01 Millennium Pharm Inc Heterocyclic compounds used as PDK1 inhibitors
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
GB0919434D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
TW201200518A (en) 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
SG186855A1 (en) 2010-06-28 2013-02-28 Merck Patent Gmbh 2,4- diaryl - substituted [1,8] naphthyridines as kinase inhibitors for use against cancer
GB201107325D0 (en) 2011-05-04 2011-06-15 Glaxosmithkline Llc Novel compounds
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
WO2013027168A1 (en) * 2011-08-22 2013-02-28 Pfizer Inc. Novel heterocyclic compounds as bromodomain inhibitors
MX2014005304A (es) 2011-10-31 2015-03-20 Xenon Pharmaceuticals Inc Biaril eter sulfonamidas y su uso como agentes terapeuticos.
EP2785717B1 (en) 2011-11-29 2016-01-13 Novartis AG Pyrazolopyrrolidine compounds
CN103183675A (zh) 2011-12-27 2013-07-03 山东轩竹医药科技有限公司 磷酸二酯酶-4抑制剂
WO2013097052A1 (en) * 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
WO2013142390A1 (en) 2012-03-21 2013-09-26 Gtx, Inc. Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors
JP6215315B2 (ja) * 2012-06-12 2017-10-18 アッヴィ・インコーポレイテッド ピリジノンおよびピリダジノン誘導体
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
BR112015022782A2 (pt) 2013-03-14 2017-07-18 Glaxosmithkline Ip No 2 Ltd composto, composição farmacêutica, combinação, e, uso de um composto
CN105121443B (zh) * 2013-04-18 2017-04-12 上海复尚慧创医药研究有限公司 蛋白激酶抑制剂
US9890166B2 (en) 2013-05-27 2018-02-13 Novartis Ag Imidazopyrrolidine derivatives and their use in the treatment of disease
US8975417B2 (en) 2013-05-27 2015-03-10 Novartis Ag Pyrazolopyrrolidine derivatives and their use in the treatment of disease
PL3004112T3 (pl) 2013-05-28 2018-02-28 Novartis Ag Pochodne pirazolo-pirolidyn-4-onu oraz ich zastosowanie w leczeniu choroby
RU2016102647A (ru) 2013-06-28 2017-08-01 Эббви Инк. Ингибиторы бромодомена
AR096758A1 (es) 2013-06-28 2016-02-03 Abbvie Inc Inhibidores cristalinos de bromodominios
US20150051208A1 (en) 2013-08-14 2015-02-19 Boehringer Ingelheim International Gmbh Pyridinones
SI3290407T1 (sl) * 2013-10-18 2020-07-31 Celgene Quanticel Research, Inc Inhibitorji bromodomene
JP6715243B2 (ja) 2014-10-27 2020-07-01 テンシャ セラピューティクス，インコーポレイテッド ブロモドメイン阻害剤

Also Published As

Publication number Publication date
PL3290407T3 (pl) 2020-09-07
TWI676619B (zh) 2019-11-11
EA201690734A1 (ru) 2016-10-31
JP2019023192A (ja) 2019-02-14
ES2930305T3 (es) 2022-12-09
PL3057586T3 (pl) 2020-05-18
CA2927567A1 (en) 2015-04-23
EP3290407A1 (en) 2018-03-07
TW202026282A (zh) 2020-07-16
RS60136B1 (sr) 2020-05-29
US20220315601A1 (en) 2022-10-06
CY1122886T1 (el) 2021-05-05
EP3640241A1 (en) 2020-04-22
HUE048371T2 (hu) 2020-07-28
MX2016005038A (es) 2016-09-13
US10941160B2 (en) 2021-03-09
RS63733B1 (sr) 2022-12-30
EP3057586B1 (en) 2019-12-04
EP3057586A4 (en) 2017-06-14
AU2019201352B2 (en) 2020-08-20
JP6445574B2 (ja) 2018-12-26
TW201605799A (zh) 2016-02-16
PE20180248A1 (es) 2018-02-02
ES2774318T3 (es) 2020-07-20
KR102311573B1 (ko) 2021-10-12
JP6734896B2 (ja) 2020-08-05
LT3640241T (lt) 2022-12-27
US9115114B2 (en) 2015-08-25
CL2018000318A1 (es) 2018-07-13
HRP20200341T1 (hr) 2020-06-12
DK3640241T3 (da) 2022-11-28
SG11201602996RA (en) 2016-05-30
SG10201804471PA (en) 2018-07-30
IL245074B (en) 2019-02-28
US20150111885A1 (en) 2015-04-23
AU2014337064A1 (en) 2016-05-05
ES2775217T3 (es) 2020-07-24
LT3057586T (lt) 2020-03-10
US9034900B2 (en) 2015-05-19
EA035727B1 (ru) 2020-07-31
US9598372B2 (en) 2017-03-21
CY1122734T1 (el) 2021-05-05
DK3057586T3 (da) 2020-03-09
US20170158709A1 (en) 2017-06-08
CN105828820A (zh) 2016-08-03
MX371386B (es) 2020-01-27
CA3148196A1 (en) 2015-04-23
BR112016008593B1 (pt) 2022-10-18
EP3640241B1 (en) 2022-09-28
DK3290407T3 (da) 2020-03-23
US20240182490A1 (en) 2024-06-06
PT3640241T (pt) 2022-11-21
NZ718981A (en) 2021-03-26
AU2014337064B2 (en) 2019-03-14
NI201600056A (es) 2016-10-11
CN105828820B (zh) 2020-01-07
LT3290407T (lt) 2020-04-10
CN108558889B (zh) 2021-11-05
SI3057586T1 (sl) 2020-04-30
PE20161065A1 (es) 2016-11-19
CR20160229A (es) 2016-10-11
PL3640241T3 (pl) 2022-12-05
US20200148703A1 (en) 2020-05-14
US20180273547A1 (en) 2018-09-27
EP4134364A2 (en) 2023-02-15
TWI771630B (zh) 2022-07-21
CA2927567C (en) 2022-04-26
SI3290407T1 (sl) 2020-07-31
US10562915B2 (en) 2020-02-18
HUE060767T2 (hu) 2023-04-28
IL256946B (en) 2019-02-28
US11884680B2 (en) 2024-01-30
BR112016008593A8 (pt) 2020-03-10
AU2019201352A1 (en) 2019-03-21
SI3640241T1 (sl) 2023-01-31
EP3290407B1 (en) 2020-01-01
PT3057586T (pt) 2020-03-13
PT3290407T (pt) 2020-04-06
US20160115134A1 (en) 2016-04-28
EP3057586A1 (en) 2016-08-24
CL2016000925A1 (es) 2017-02-03
EP4134364A3 (en) 2023-06-14
WO2015058160A1 (en) 2015-04-23
SA516370965B1 (ar) 2020-08-05
KR20160101899A (ko) 2016-08-26
US10023592B2 (en) 2018-07-17
US20150183784A1 (en) 2015-07-02
CN108558889A (zh) 2018-09-21
JP2016533397A (ja) 2016-10-27
FI3640241T3 (fi) 2023-01-13
PH12016500722A1 (en) 2016-05-30
RS60002B1 (sr) 2020-04-30
IL245074A0 (en) 2016-06-30
HRP20221389T1 (hr) 2023-01-06

Similar Documents

Publication Publication Date Title
HRP20200492T1 (hr) Bromodomenski inhibitori
JP2016533397A5 (hr)
RU2486181C2 (ru) Пиримидилциклопентаны как ингибиторы акт-протеинкиназ
CA2582029A1 (en) Aryl nitrogen-containing bicyclic compounds and methods of use
RU2005136655A (ru) Производные пиримидина, пригодные для лечения болезней, опосредованных сrth2
RU2017134866A (ru) Соединения бензазепина дикарбоксамида
HRP20161177T1 (hr) Modulator glukagonskog receptora
HRP20120656T1 (hr) Derivati indazolil amida za liječenje poremećaja posredovanih glukokortikoidnim receptorom
CA2432000A1 (en) Pyrimidineamines as angiogenesis modulators
RU2013106755A (ru) 1,4,5,6-тетрагидропиримидин-2-иламины
HRP20240994T1 (hr) Spoj inhibitora jak i njegova uporaba
CA2564355A1 (en) Protein kinase modulators and method of use
JP2021502387A5 (hr)
RU2015128025A (ru) Ингибиторы сомт
RU2015132181A (ru) Фтор-[1,3]-оксазины в качестве ингибиторов васе1
RU2016134947A (ru) Производные диаминопиримидин бензолсульфона и их применение
JP2019513804A5 (hr)
RU2016103938A (ru) Модуляторы протеин-тирозинкиназы и способы их применения
RU2013130925A (ru) Оксимовые соединения в качестве средств для повышения уровня холестерина высокой плотности
JP2017503837A5 (hr)
HRP20180272T1 (hr) Benzamidi
RU2013132930A (ru) Производное пиразола
RU2018131775A (ru) 6-арил-4-морфолин-1-илпиридоны, пригодные для лечения рака или диабета
JP2020503293A5 (hr)
JP2009520021A5 (hr)